BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38582393)

  • 1. Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics.
    Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
    Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-coding RNAs (ncRNAs) and multidrug resistance in glioblastoma: Therapeutic challenges and opportunities.
    Subaiea GM; Syed RU; Afsar S; Alhaidan TMS; Alzammay SA; Alrashidi AA; Alrowaili SF; Alshelaly DA; Alenezi AMSRA
    Pathol Res Pract; 2024 Jan; 253():155022. PubMed ID: 38086292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs involved in the EGFR pathway in glioblastoma.
    Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
    Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of noncoding RNAs in the EGFR signaling pathway in lung cancer.
    Mohan S; Hakami MA; Dailah HG; Khalid A; Najmi A; Zoghebi K; Halawi MA
    Pathol Res Pract; 2024 Jan; 253():155016. PubMed ID: 38070221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.
    Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC
    Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
    Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
    Taylor TE; Furnari FB; Cavenee WK
    Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
    Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
    Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
    EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1.
    Lulli V; Buccarelli M; Ilari R; Castellani G; De Dominicis C; Di Giamberardino A; D Alessandris QG; Giannetti S; Martini M; Stumpo V; Boe A; De Luca G; Biffoni M; Marziali G; Pallini R; Ricci-Vitiani L
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
    Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
    Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.
    Lo HW
    Curr Mol Pharmacol; 2010 Jan; 3(1):37-52. PubMed ID: 20030624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
    Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
    Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
    Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS
    Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
    Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
    Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.
    Gao X; Xia X; Li F; Zhang M; Zhou H; Wu X; Zhong J; Zhao Z; Zhao K; Liu D; Xiao F; Xu Q; Jiang T; Li B; Cheng SY; Zhang N
    Nat Cell Biol; 2021 Mar; 23(3):278-291. PubMed ID: 33664496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
    Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
    Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
    Fang R; Chen X; Zhang S; Shi H; Ye Y; Shi H; Zou Z; Li P; Guo Q; Ma L; He C; Huang S
    Nat Commun; 2021 Jan; 12(1):177. PubMed ID: 33420027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.